La page que vous recherchez est disponible en anglais.sur notre site global www.capsugel.com
Pour visiter cette page sélectioner continuer.
Oct, 23, 2014
Scientific posters, symposia and specialty seminars round out company's presence
Morristown, N.J., October 23, 2014 – Capsugel scientists will discuss a range of advancements – including bioavailability enhancement and multiparticulate technologies, dry powder inhalation (DPI) technologies, and alternate-polymer and other specialized capsule technologies – at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs November 2-6 in San Diego, Calif. The company will also showcase specialized equipment to support key technologies in encapsulation and bioreactor process control.
"It’s an exciting time to be a scientist at Capsugel. Our advanced science and engineering, expanded technology offerings, and the growing synergies between our Hard Capsule and Dosage Form Solutions business units are leading to new opportunities to create value for our customers,” said Keith Hutchison, Ph.D., Senior Vice President, Research & Development, Capsugel. “At AAPS, we look forward to discussing our approach to addressing customers’ most-pressing formulation challenges, including low and variable drug absorption, high-potency/low-dose requirements and modified drug release profiles and to demonstrating our unique ability to design, develop and manufacture both state-of-the-art capsules and finished dosage forms."
Company scientists will present 20 technical posters and host a series of seminars on key innovations. Highlights include:
Specialized equipment that will be featured at the booth includes Capsugel’s new Modular Automated Sampling Technology™ platform, or MAST, and its Xcelodose® precision powder micro-dosing system. MAST is an automated, aseptic bioreactor sampling system that will help advance the bioprocess industry toward real-time testing, predictive control and overall bioprocess guidance. Capsugel’s Xcelodose® system shortens drug development time, speeds first-in-human trials and lowers costs by reducing the need for formulation and stability studies before API proof of concept is established.
Visit Capsugel’s booth #1422 to learn about innovative dosage technology and manufacturing solutions for the pharmaceutical industry. An overview of poster presentations and seminars can be found here. Schedule a meeting with Capsugel in advance here, and follow updates about the meeting at www.capsugel.com.
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.